Genmab — April 2020

[Bulder]

Come to think about it: These titles do not include late breaking. So still a chance.

[E_L]

to be honest; if it will be now, i think late breaker would be most likely

[E_L]

but Sukkeralf also suggested ESMO as alternative, very well possible, late in the year filing?

[Bulder]

Yes, or maybe EHA, 2 weeks after asco

[KWC]

Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program
Media Release

Copenhagen, Denmark, April 29, 2020

Six industry sponsored abstracts regarding Genmab and Genmab partnered programs selected for presentation at ASCO20 Virtual Scientific Program, including data from the epcoritamab (DuoBody-CD3xCD20) Ph I/II dose-escalation study.

Genmab A/S (Nasdaq: GMAB) announced today that six industry sponsored abstracts regarding Genmab and Genmab partnered programs were accept

[KWC]

accepted for presentation at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, taking place from May 29 to 31, 2020. The titles of the abstracts are currently available on the ASCO Meeting Library, with the full abstracts scheduled to be published on May 13, 2020. A list of the abstracts is provided below, and includes one on epcoritamab, one on tisotumab vedotin (Trial in Progress) and four on daratumumab. Beginning Friday, May 29, 2020 at 8:00 AM EDT, poster s

[KWC]

“Although this year’s ASCO will be a virtual conference due to the difficult and unprecedented circumstances, we are pleased that data on our proprietary pipeline and partnered programs has been accepted for presentation at this prestigious conference. We are particularly looking forward to the data presentation that will demonstrate continued solid progress in our development of epcoritamab (DuoBody-CD3xCD20),” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

[GeorgeBest]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-asco20-virtual-scientific

[KWC]

[KWC]

Epcoritamab:
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/ refractory B-NHL: Complete dose escalation data and efficacy results from a phase I/II trial - Virtual poster presentation

Tisotumab Vedotin:
Phase Ib/II trial of tisotumab vedotin ± bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) - Virtual poster presentation

Daratumumab (Submitted by Janssen Biotech, Inc.):
Cort

[KWC]

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study - Virtual poster presentation

[Bulder]

Hvorfor nævner de ikke Teclistamab og Amivantamab? Det er ellers de tunge MM-drenge (og piger) der er med i Teclistamab.

[Bulder]

Nu virker søgemaskinen. Fandt denne her: A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results. Skal satme under observation.

[Bulder]

GSK's ADC er der også: DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.

[Bulder]

Og i 1. linje: DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

[Bulder]

Men dreamm-9 kan der umuligt være data fra. Det er nok bare en præsentation af studiet. Så sent som februar var dreamm-9 kun på planlægningsstadiet.

[Solsen]

Mon ikke JNJ kunne vælge at holde lav profil mht kombinationsmulighederne til dara af konkurrencehensyn. De er i fuld gang med at afprøve https://clinicaltrials.gov/ct2/show/NCT04108195

[Bulder]

Det kunne måske forklare Teclistamab, men ikke Amivantamab?

[Solsen]

BTD = late breaker

[Bulder]

?